Provided by Tiger Fintech (Singapore) Pte. Ltd.

AlloVir, Inc.

9.81
0.0000
Volume:- -
Turnover:94.38K
Market Cap:49.21M
PE:-0.84
High:9.81
Open:9.81
Low:9.81
Close:9.81
52wk High:24.15
52wk Low:7.96
Shares:5.02M
Float Shares:1.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.7340
EPS(LYR):-11.7340
ROE:-45.37%
ROA:-22.33%
PB:0.43
PE(LYR):-0.84

Loading ...

Press Release: Kalaris Announces Closing of Merger with AlloVir

Dow Jones
·
Mar 19

AlloVir Shareholders Approve Merger With Kalaris Therapeutics

MT Newswires Live
·
Mar 13

AlloVir trading halted, news pending

TIPRANKS
·
Jan 16

BRIEF-Allovir's Reverse Stock Split Proposal Passes With 96.2 Mln Votes For

Reuters
·
Jan 10

Allovir Inc - Reverse Stock Split Proposal Passes With 96.2 Mln Votes for, 12.1 Mln Against

THOMSON REUTERS
·
Jan 10

AlloVir CEO Departs, CFO Steps In

Dow Jones
·
Dec 21, 2024

BRIEF-Allovir Inc - Diana Brainard Steps Down As CEO Of Allovir

Reuters
·
Dec 21, 2024

AlloVir Appoints Vikas Sinha as New CEO

TIPRANKS
·
Dec 21, 2024

Allovir Inc - Diana Brainard Steps Down as CEO of Allovir

THOMSON REUTERS
·
Dec 21, 2024

Allovir Inc: Appointed Vikas Sinha as Company's Chief Executive Officer and "Principal Executive Officer

THOMSON REUTERS
·
Dec 21, 2024

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Nov 08, 2024

AlloVir and Kalaris Merge to Advance Retinal Therapies

TIPRANKS
·
Nov 08, 2024

Allovir Inc - Exchange Ratio Assumes Valuation for Allovir of $116.0 Mln and Valuation for Kalaris of $347.0 Mln

THOMSON REUTERS
·
Nov 08, 2024

Allovir - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Kalaris Termination Fee of $3.5 Mln

THOMSON REUTERS
·
Nov 08, 2024

AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics

Dow Jones
·
Nov 08, 2024

AlloVir Signs Merger with Kalaris Therapeutics

MT Newswires Live
·
Nov 08, 2024

BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases

Reuters
·
Nov 08, 2024

Allovir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

THOMSON REUTERS
·
Nov 08, 2024

Allovir Inc - Stockholders to Own 25.05% of Combined Company Post-Merger

THOMSON REUTERS
·
Nov 08, 2024

Allovir Inc - Combined Company to Operate as Kalaris Therapeutics, Inc. and Trade as Klrs

THOMSON REUTERS
·
Nov 08, 2024